MLTX today
$13.15-$0.36 (-2.66%)close Nov 12, 2026Trend
DailyDowntrend (confirmed)
4 hourSymmetric Triangle
1 hourLeaning Bearish
15 minBearish
5 minStrong Bullish
Daily trend turns up above $62.75
Key levels
Resistance$14.63
Resistance$13.33
Support$11.71
Support$10.70
Latest news & SEC filings
AnalystChardan starts MoonLake Immunotherapeutics coverage with Buy rating, $57 target
AnalystBTIG Keeps Buy Rating on MoonLake Immunotherapeutics
LegalHagens Berman files suit claiming MoonLake Immunotherapeutics misled investors
EarningsMoonLake Immunotherapeutics Posts Q3 2026 Financials
SEC FilingMoonLake Immunotherapeutics filed a report on a major company event (Form 8-K)
All MLTX news →About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on treatments for inflammatory conditions of the skin and joints. Its main candidate, sonelokimab, is a Nanobody designed to block two interleukin-17 cytokines, licensed from Merck Healthcare KGaA, and is being tested in hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company operates in the United States and Europe, serving patients with these diseases and their physicians.
Based on the company's 10-K filed Feb 25, 2026.
Nasdaq · Healthcare
MoonLake Immunotherapeutics (MLTX)
What Is the Price Target for MLTX?
SEPT Low Target
$34.00
SEPT Mid Target
$40.00
SEPT High Target
$46.00
Analyst Consensus
$40.00
Is MLTX a Buy or Sell Right Now?
Thesis
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for MLTX.
Start Free Trial →Is MLTX Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$32.66
15
Moat Score
NONE
1/9
Piotroski Score
1.0
Altman Z-Score
What Is Smart Money Doing with MLTX?
Insider Signal
SELLING
0 buys / 6 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
ACCUMULATING
Short Squeeze Risk
LOW
Signal: NEUTRAL
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →MLTX Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
-86.77%
FCF Growth YoY
-67.4%
Revenue Trend
UNKNOWN
Dark Pool Trades for MLTX
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for MLTX, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 15:00:30 | $13.15 | 1,200 | $$16K | MIDPOINT |
| 14:57:43 | $13.17 | 2,222 | $$29K | SELL |
| 14:48:30 | $13.22 | 2,900 | $$38K | MIDPOINT |
| 14:48:30 | $13.22 | 1,300 | $$17K | MIDPOINT |
| 14:48:19 | $13.22 | 8,500 | $$112K | SELL |
5 dark pool trades shown · $$213K preview volume
Real-time institutional flow, block trades, and net positioning
What Traders Are Saying About MLTX
1 postsSEPT Investing hosts an active community of 3,500+ traders sharing real-time analysis, trade setups, and market discussion for MLTX. Join verified traders discussing price action, dark pool alerts, options flow, and AI-powered market intelligence.
Zone Setup -- $MLTX (MoonLake Immunotherapeutics) Price: $18.95 | Zone: $18.57 to $23.29 Conviction: HIGH | Analyst upside: +50% Near support (8% of range) — reversal watch. Strong positive news (4+...
Join 3,500+ traders discussing MLTX in real-time
Trade ideas, setups, dark pool alerts, and AI-powered analysis
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for MoonLake Immunotherapeutics (MLTX) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →MLTX — frequently asked questions
What is MLTX stock price today?
MoonLake Immunotherapeutics (MLTX) is at $13.15, down 2.66% (-$0.36) at the Nov 12, 2026 close.
Why is MLTX stock moving today?
Latest MLTX news — Nov 6, 2026: Chardan starts MoonLake Immunotherapeutics coverage with Buy rating, $57 target · Nov 6, 2026: BTIG Keeps Buy Rating on MoonLake Immunotherapeutics
What is the MLTX price target?
The average analyst price target for MLTX is $40.00, ranging from $29 to $50, based on 4 analysts.
What do analysts rate MLTX?
Analyst ratings for MLTX: 0 Buy, 8 Hold, 0 Sell — consensus Hold.
Did MLTX beat earnings?
MLTX last reported on Aug 10, 2026: EPS -$0.84 vs -$0.91 expected — a beat of 7.6%.
Does MLTX pay a dividend?
MLTX does not currently pay a dividend.
How much debt does MLTX have?
MoonLake Immunotherapeutics reported $100M of debt and $478M of cash (Jun 30, 2026).
What are MLTX support and resistance levels?
Support: $11.71, $10.70, $9.46. Resistance: $13.33, $14.63, $15.47.
What are insiders doing with MLTX?
Insider activity: SELLING, 0 buys and 6 sells in the last 90 days.
What is the latest news on MLTX?
Nov 6, 2026: Chardan starts MoonLake Immunotherapeutics coverage with Buy rating, $57 target · Nov 6, 2026: BTIG Keeps Buy Rating on MoonLake Immunotherapeutics · Nov 6, 2026: Hagens Berman files suit claiming MoonLake Immunotherapeutics misled investors